Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E. Galimberti F, et al. Among authors: ma t. Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22. Int J Oncol. 2012. PMID: 22923130 Free PMC article.
Evidence for the ubiquitin protease UBP43 as an antineoplastic target.
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Guo Y, et al. Among authors: ma t. Mol Cancer Ther. 2012 Sep;11(9):1968-77. doi: 10.1158/1535-7163.MCT-12-0248. Epub 2012 Jul 2. Mol Cancer Ther. 2012. PMID: 22752428 Free PMC article.
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E. Ma T, et al. Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16. Mol Cancer Ther. 2013. PMID: 23686769 Free PMC article.
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. Dragnev KH, et al. Among authors: ma t. Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376. Cancer Prev Res (Phila). 2011. PMID: 21636548 Free PMC article. Clinical Trial.
Mice lacking G0S2 are lean and cold-tolerant.
Ma T, Lopez-Aguiar AG, Li A, Lu Y, Sekula D, Nattie EE, Freemantle S, Dmitrovsky E. Ma T, et al. Cancer Biol Ther. 2014 May;15(5):643-50. doi: 10.4161/cbt.28251. Epub 2014 Feb 20. Cancer Biol Ther. 2014. PMID: 24556704 Free PMC article.
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.
Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E. Chinyengetere F, et al. Among authors: ma t. BMC Cancer. 2015 Nov 10;15:886. doi: 10.1186/s12885-015-1883-8. BMC Cancer. 2015. PMID: 26555296 Free PMC article.
Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Guo Y, et al. Among authors: ma t. Cancer Res. 2010 Dec 1;70(23):9875-85. doi: 10.1158/0008-5472.CAN-10-1100. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935222 Free PMC article.
8,004 results